

Review Article

A Critical Review on the Role of Probiotics in Lung Cancer Biology and Prognosis

Sumel Ashique^{a,*}, Neeraj Mishra^b, Ashish Garg^c, Nitish Kumar^d, Zuber Khan^e, Sourav Mohanto^f, Dinesh Kumar Chellappan^g, Arshad Farid^h, Farzad Taghizadeh-Hesary^{i,j,*}

^a Department of Pharmaceutical Sciences, Bengal College of Pharmaceutical Sciences & Research, Durgapur 713212, West Bengal, India

^b Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior 474005, MP, India

^c Guru Ramdas Khalsa Institute of Science and Technology, Pharmacy, Jabalpur, MP 483001, India

^d SRM Modinagar College of Pharmacy, SRM Institute of Science and Technology (Deemed to be University), Delhi-NCR Campus, Modinagar, Ghaziabad, Uttar Pradesh 201204, India

^e Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India

^f Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka 575018, India

^g Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia

^h Gomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail Khan 29050, Pakistan

ⁱ ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

^j Department of Clinical Oncology, Iran University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article history:

Received 20 February 2024

Accepted 10 April 2024

Available online 6 May 2024

Keywords:

Probiotics

Lung cancer

Gut–lung axis

Immune system

ABSTRACT

Lung cancer remains the leading cause of cancer-related deaths worldwide. According to the American Cancer Society (ACS), it ranks as the second most prevalent type of cancer globally. Recent findings have highlighted bidirectional gut–lung interactions, known as the gut–lung axis, in the pathophysiology of lung cancer. Probiotics are live microorganisms that boost host immunity when consumed adequately. The immunoregulatory mechanisms of probiotics are thought to operate through the generation of various metabolites that impact both the gut and distant organs (e.g., the lungs) through blood. Several randomized controlled trials have highlighted the pivotal role of probiotics in gut health especially for the prevention and treatment of malignancies, with a specific emphasis on lung cancer. Current research indicates that probiotic supplementation positively affects patients, leading to a suppression in cancer symptoms and a shortened disease course. While clinical trials validate the therapeutic benefits of probiotics, their precise mechanism of action remains unclear. This narrative review aims to provide a comprehensive overview of the present landscape of probiotics in the management of lung cancer.

© 2024 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Introduction

Recent studies have suggested that lung cancer ranks as the second highest cause of mortality worldwide.¹ Several authors have established that smoking accounts for over 90% of lung cancer incidences. In addition, air pollution and several other respiratory toxins are being recognized as important risk factors for lung carcinogenesis. There are several factors that largely influence the pathological condition of a disease, namely, the influx of bacterial colonies, immunological removal of such colonies, adaptability of the bacterial strains to host threat, and the capability of such microbes to reproduce under specific environmental conditions.

Although the health of individuals with early-stage lung cancer has significantly improved during the past few decades, the total 5-year survival rate is reported to be just over 9% for males and 15% for women, despite developments and numerous treatment advancements.² Hence, innovative and advanced approaches are needed to prevent and treat lung cancer.³ Available evidence has put forward that except for tobacco smoking, which is a well-known risk factor for lung cancer, several other risk factors can be involved, including genetic factors, infections (HPV, HIV, and EBV), previous lung disease (e.g., chronic obstructive pulmonary disease, tuberculosis), air pollution, radon or asbestos exposure, improper diet, marijuana smoking, and alcohol consumption.⁴ However, there are cases with lung cancer who have never smoked and do not have the aforementioned risk factors. This issue has sparked curiosity among researchers worldwide to explore other factors involved in the pathogenesis of lung cancer.

* Corresponding authors.

E-mail addresses: ashiquesumel007@gmail.com (S. Ashique), Farzadth89@gmail.com, taghizadeh_hesary.f@iums.ac.ir (F. Taghizadeh-Hesary).

Trillions of microorganisms have been reported to reside within the human gastrointestinal system, and the bacterial interplay between the microbiota and other body cells is crucial for preserving immunological homeostasis in the gut milieu.^{5–7} The World Health Organization (WHO) and the Food and Agriculture Organization (FAO) have defined *probiotics* as live microorganisms that bestow a favorable impact on human health when administered adequately.^{8,9} Potential nutritional and physiological benefits of gut microbiota include nutrient utilization, infection resistance, modification of gut microbial groups, immune reinforcement, and regulation of the host metabolism.¹⁰ Probiotics that boost hosts' health have garnered much attention recently. Clinical studies have revealed that probiotics can improve immune function and reduce the severity and incidence of lung diseases.¹¹ The idea of regulating immunomodulation and governing pulmonary homeostasis through healthy bacteria by gut–lung interaction is reinforced using beneficial probiotics.

In conclusion, while lung cancer remains a formidable global health challenge with a low 5-year survival rate, the multifaceted nature of its development, involving various risk factors such as smoking, genetic predisposition, and environmental exposures, necessitates innovative approaches. Beyond traditional risk factors, the emerging field of research on the gut–lung interaction highlights the potential of probiotics in modulating immune function and influencing lung health, providing a promising avenue for further exploration and the development of novel strategies for lung cancer prevention and management.

This review aims to comprehensively examine the role of probiotics in the development, progression, and treatment of lung cancer, with a specific focus on their impact through the gut–lung axis and immune modulation. We seek to explore the potential mechanisms by which probiotics may influence lung cancer biology, acknowledging the current gaps in understanding their precise mechanisms. Additionally, this review will identify key areas for future research, particularly the need for clinical trials that delineate the efficacy of specific probiotic strains, optimal dosages, and treatment durations. Recognizing the variability in individual responses to probiotics, the prospects for personalized probiotic therapies tailored to individual genetic backgrounds, microbiome compositions, and lifestyle factors will also be considered. Furthermore, the integration of probiotics with conventional lung cancer treatments, evaluating potential synergistic effects, safety concerns, and regulatory considerations will also be discussed. By doing so, this review aims to shed light on the promising yet complex role of probiotics in lung cancer management, setting the stage for future investigations that could lead to novel therapeutic strategies.

Methods

The relevant literature was searched using Web of Science, PubMed, and Science Direct in English by December 2023. The databases were searched using the following keywords: “probiotics”; “microbiome”, “lung cancer”, “gut–lung axis”, “immune system” and their equivalent terms. Case reports, commentary, and Editorial papers were not included in this review.

Gut–lung axis

The gastrointestinal tract and the lungs share a common embryonic origin.¹ In addition, they can physically interact due to the possibility of ingested germs reaching the gastrointestinal and respiratory systems, as well as the ability of gastroesophageal contents to enter the lungs through inhalation.¹² The gut–lung axis (GLA) has been identified as playing a critical role in both

health and disease, underpinned by the extensive interaction between gastrointestinal and pulmonary systems.¹³ Similarities in the mucosa covering the stomach and lungs and those of the other organs that make up the mucosal immune system (MIS), foster comparable dynamics involving exchanges between the immune system and associated microbiota.¹⁴ As a result of their indirect connections with the lymphatic and circulatory systems, the immune response also influences the scenario systematically; however, the extent of immunological reaction is mostly dependent on the location of the very first encounter.¹⁵ Firmicutes and Bacteroidetes are the common bacterial phyla in the lungs and intestines of healthy humans. The overall microbial ecology is influenced by the interplay between lungs and intestines, partly because of nutrient interchange and antimicrobial bio-actives.^{16–18} The relationship between the microbial population of the lung and the gut is vague, and how the gut microbiota impacts the lungs, intestine, and other systems is a topic of further investigation.¹⁹ Antigen-presenting cells (e.g., dendritic cells), B cells, T cells (esp. T_{reg} cells), and intestinal epithelial cells are among the most stimulated cells by microbial communities.²⁰ There have been several progressive studies explaining the molecular foundation of entero-pulmonary interactions. These studies have mainly reported on antimicrobial peptides (AMPs) and secretory IgA, as well as the formation of microbial metabolites like the kynurenine pathway.²¹ The incidence of asthma, lung infections, and several other respiratory diseases have now been linked to dysbiosis.²² Brown et al. revealed the physiological benefits of the gut microbiota.²³ Several gut microbiotas are involved in the synthesis of interleukins, like IL-17A, which is essential for the increased production of granulocyte-macrophage-stimulating factors in the lung. These factors activate the killing and elimination of potential macrophages in the lung alveoli.²⁴ Furthermore, lung microbiota modification causes both local and systemic immune alterations. These events may promote intestinal immune response, as seen in *Staphylococcus aureus*-induced pneumonia, resulting in sepsis and apoptotic events in the gut.²⁵

Lung microbiomes and host immunity

The mucus layer in the intestine acts as a physical barrier that separates the luminal contents of the gut, including digested food and microorganisms, from the underlying epithelial cells of the intestinal lining. This barrier helps prevent direct contact between potentially harmful bacteria and the epithelium, which can trigger inflammatory responses or infections. The mucus layer also contains immunoglobulins, antimicrobial peptides, and other immune components that help defend against invading pathogens. Additionally, the mucus layer serves as a habitat for certain beneficial bacteria, which can compete with harmful bacteria for resources and space.²⁶ The recent identification of a novel CD4⁺ T cell subset known as Th17 has revolutionized the comprehension of the underlying causes of numerous chronic immune-mediated conditions. Particularly in regions of the body that interact closely with the microbial environment, such as the gastrointestinal and respiratory tracts, as well as the skin, where Th17 cells are predominantly found. When the immune response against self-components becomes dysregulated in these tissues, it can lead to the development of chronic inflammatory diseases.²⁷ By influencing the host's sensitivity to different pathogenic agents and therapeutic effects, the microbiota controls the host's immune functionality. The ability of hosts to detect and stop bacterial or fungal invasions and illnesses results from the dynamic interplay between the microbiota and the immune systems. Secretory IgA (SIgA) plays a vital role as the initial defense barrier safeguarding the intestinal epithelium against enteric toxins and pathogenic microorganisms.

Through a process referred to as immune exclusion, SIgA actively contributes to the removal of antigens and pathogenic microorganisms from the intestinal lumen. It achieves this by obstructing their access to epithelial receptors, ensnaring them within the mucus layer, and facilitating their elimination through peristaltic and mucociliary activities.²⁸ In the human intestine, a stable state of equilibrium is upheld through precise regulation of microbial levels and the corresponding immune response. When this balance falters, it can lead to various pathological conditions. Toll-like receptors (TLRs), which are a part of the innate immune system, play a pivotal role as intermediaries connecting the intestinal epithelial barrier, the microbiota, and the immune system. The TLR pathway, which is typically activated in response to pathogens, contributes to the development of numerous infectious and inflammatory diseases.²⁹ Preclinical studies on germ-free mice have shown significant immunological abnormalities, including a compromised mucous layer, underlining the gut microbiota's role in immune homeostasis. This effect may be attributed to reduced immunoglobulin secretion.^{30,31} IgA reportedly controls bacterial pathogenicity in the stomach primarily by preventing bacterial adhesion to mucosal epithelial cells.²⁸ Interleukin 17 (IL-17) stands as a crucial proinflammatory cytokine within the T helper 17 (Th17) pathways. It plays a pivotal role in both the clearance of specific pathogens and the development of various inflammatory diseases. This cytokine, along with its counterpart IL-17F, is expressed by distinct types of T cells, particularly Th17 cells, as well as certain other lymphocytes. These cytokines are central players in regulating the immune response during host defense and in the context of various inflammatory disorders.³² The delicate balance of commensal bacteria is more likely to be upset and exogenous pathogens are more likely to infect low-density micro-ecologies with unstable microbiomes.³³ High commensal microbiota density may improve the clinical effectiveness of vaccination in infants.³⁰ The clearance of certain pathogens is aided by IL-17, where the gut microbiota may control and boost Th17 responses.^{34,35} IL-17 pathway is associated with various diseases such as airway disease (asthma and obliterative bronchiolitis), sarcoidosis, and bone marrow transplant-related pneumonitis.^{10,36–38} Iida et al. reported that microbiota of lungs regulates gene expression of various inflammatory cytokines (IL-5, IL-10, and IFN). Furthermore, their experiments on lungs of neonatal mice showed programmed death ligand 1 (PD-L1) which was expressed at a higher level as compared to germ-free mice. There was also increase in the number of CD11b⁺dendritic cells (DCs) and FoxP3⁺CD25⁺T_{reg} cells.³⁹ Steed et al. demonstrated that desaminotyrosine (DAT), a metabolite produced by *Clostridium orbiscindens*, defends the host from influenza by increasing the type I IFN signaling and thereby decreasing lung cancer pathogenesis.⁴⁰ Ichinohe et al.⁴¹ also reported data showing that commensal microbiota might regulate immune responses in airway mucosa by inflammasomes and convey activation signals (immune signals) after influenza virus infection remains in a steady state. Inulin, a fermentable fiber, has been reported to change the composition of the gut microbiome and related metabolites, including short chain fatty acids. It is also found to promote resistance to influenza-virus infection via decreasing neutrophil-induced injury and promoting the antiviral CD8⁺ T cell responses in mice. Additionally, enriched lung microbiota due to oral microbiomes can be related to Th17 inflammation. The composition of the lung microbiota is shown to critically affect TLR4 responses.²⁵ Additionally, it has been demonstrated that the commensal microbiota promotes the growth and activation of Vg6⁺Vd1⁺ T cells in lung cancer.⁴¹ However, there is no universally accepted definition of a healthy or advantageous lung microbiome, in part because of our incomplete understanding of how the lung's resident microbiome and host immunity are related.

Lung microbiome and host metabolism

Intestinal microbiome changes that deregulate the host metabolism have been thoroughly explored.^{42,43} According to reports, microbiome-derived carcinogens, including acetaldehyde and deoxycholic acid, are crucial in developing esophageal and liver cancers.^{44,45} Visconti et al. found metagenomic shotgun sequencing useful in the characterization of the gut microbiota while also analyzing the metabolites found in the blood and feces.⁴⁶ Their results confirmed an association between gut bacterial metabolic pathways and metabolites in blood and feces.⁴⁶ Through a variety of physiological processes, metabolism is crucial for preserving the homeostasis of the human body.⁴⁷ Additionally, a recent study was conducted to explore the association between host metabolism and the lung microbiome. Weinberg et al. showed that lung microbiota can modulate the phenotypes of lung cancer tumor microenvironment components and can regulate the metabolic and inflammatory pathways.⁴⁸ Given the importance of tumor microenvironment in cancer progression and treatment resistance,⁴⁹ this finding can be applied in future studies to modulate the cancer biology. Cribbs et al. found that the glycerophospholipid pathways play a crucial role in the development of pneumonia in patients with AIDS. This study led to the identification of specific metabolic profiles associated with bacterial taxonomic resolution through sequencing the 16S gene in the bronchoalveolar lavage.⁵⁰ In addition, *Pseudomonas aeruginosa*-based primary metabolites utilize substrates produced by other microbes, like *Rothia mucilaginosa*, which may take part in the etiology of cystic fibrosis.⁵¹ One of the potent metabolites is SCFA, which is produced in large amounts by microbiota in the large intestine which acts as a major signaling biomolecule in host cells. Even though various research investigations have focused on the role of SCFA in the host gut and immunity, its effects on the respiratory system, epithelium, and immune system remain largely unknown. *S. aureus* is one of the bacteria that animals are more likely to encounter, which may be influenced by the pulmonary Th17 immunity.⁵² Furthermore, several research findings have revealed that altering the gut microbiota in preclinical models may change the host immunity and delay response to infection.⁴¹

Microbiota and lung cancer

Recent research has elucidated the complex interplay between microbial communities, tumor development, and immune cell response in the context of cancer. They elucidated the molecular pathways involved in oncogenesis and their potential significance. However, recent literature has revealed a robust bidirectional link between gut dysbiosis and lung oncogenesis. It is well-known that microorganisms can initiate tumor progression, mainly by generating bacterio-toxins and other pro-inflammatory factors.^{1,53} Due to the large surface area of the mucosal site and the constant connection with the outside environment, the lung is vulnerable to diverse microbes and environmental pollutants.

Lungs, for long, had been thought to be free from microbial contamination, but recent studies have revealed that they can be the home of a diverse commensal bacteria.⁵⁴ The growth of such microbes is initiated through numerous factors, such as the presence of new bacteria, mechanical and immunological clearance, and the capability of microbes to reproduce under particular environmental conditions⁵⁴ (Fig. 1). Interestingly, these microbial populations appeared to be reduced in diseased conditions such as cystic fibrosis, chronic obstructive pulmonary disease, and cancer.^{55,56} This finding clearly indicates an underlying complementary physiological role of these microbiotas to protect the lungs from infections and boost our immune system. To date, limited




Fig. 1. The function of the microbiome in lung cancer. Schematic illustration of lung microbiota to maintain homeostasis and cancer development. In the biology of lung cancer, the microbiota plays a number of functions and employs a range of techniques. The protagonists of the tumor microenvironment are bacteria found in the lungs and upper respiratory system, as well as those with intra-tumor and intracellular locations. The gut microbiota is crucial in influencing how the immune system reacts and how inflamed the body is. This is in addition to the bacteria involved in bloodstream translocation events. It's also possible that certain bacterial toxins with the potential to activate oncogenic pathways might alter lung function. Additionally, cigarette smoke and pollution are the two main causes of the dysbiotic changes in the lungs. Finally, the microbiome may affect metastatic pathways by increasing the production of vascular endothelial growth factors and promoting inflammation.

research has been done on the lung microbiota than on the gastrointestinal tract.

In a study conducted in non-smoking female patients with lung adenocarcinoma, a correlation was established between cancer stage and microbiota.⁵³ In addition, two correlations (positive and negative) were established. A positive correlation was established between one set of microbiotas (*Faecalibacterium* as *FB* and *T* category) and primary tumor size. In contrast, a negative correlation was established between other microbiota (*Fusicatenibacter saccharivorans* and *Bacteroides*) and tumor size. Epidermal growth factor receptor (EGFR)-wild-type patients have abundant *Bifidobacterium* and *FB*, whereas *Blautia* was relatively low compared to the EGFR-mutated population.⁵⁷ It is difficult to determine whether these changes had occurred before or after the development of cancer. It has been demonstrated that *Bacteroides* and *Faecalibacterium* can individually upregulate T-cells in the cancer lesion, followed by inhibiting proliferative cells and can activate T_{reg} cells, respectively.⁵⁸ Thus, these microbiotas may play a significant role in targeted cancer treatment as their biochemical metabolites may adversely affect the immune system. A few Gram-negative bacteria (*Enterobacter*, *Haemophilus influenzae*, and *Escherichia coli*) are capable of colonizing lung cancer. Patients with lung cancer showed low levels of *Firmicutes* and *Proteobacteria* compared to healthy individuals, whereas healthy individuals exhibited high numbers of *Bacteroidetes* and *Firmicutes* bacteria.⁵⁹ These microbiotas persisted irrespective of how the bacteria in cancer evolved. Additionally, the gut microbiota and its metabolites trigger the toll-like receptor (TLR) response, which causes T lymphocytes to spread to distant areas

when they pass through the epithelial barrier and enter the circulation.⁶⁰

Studies have revealed a link between *Enterococcus hirae* and small cell lung cancer (SCLC) wherein bacteria were found to move from the gastrointestinal tract and enhance a tumor-specific response by activating TLR and subsequently triggered the formation of memory responses.⁵³ There is growing proof that the causes of inflammation and bacterial infections may encourage the intestinal microbiota's transition from mutualism to a pro-carcinogenic form. Innumerable bacteria have been extensively investigated in terms of their molecular mechanisms, and researchers have explored their potential as a novel approach to cancer treatment.⁶¹ Within the realm of omics disciplines, proteomics plays a crucial role in the study of bacterial toxins. Advancements in proteomics have significantly improved the understanding of bacterial toxins, facilitating their characterization and contributing to the development of anti-cancer drugs based on these toxins.⁶² Bacterial endotoxins, such as LPS, are capable of entering the bloodstream through a leaky gut and may trigger systemic inflammation, potentially affecting the lung microenvironment. They may promote inflammatory responses that could potentially contribute to lung cancer development or progression.⁶³ Altered gut microbiota composition has been linked to various diseases, including cancer. However, the specific gut microbiota profile in lung cancer patients has remained relatively unexplored. Zheng and colleagues conducted a study⁶⁴ where they discovered a significant shift in the composition of gut microbiota in individuals with lung cancer compared to healthy individuals. In this study, the researchers analyzed the gut microbiota composition in a discovery group




Fig. 2. The interactions between lung cancer tumor microenvironment and lung microbiota.

consisting of 42 early-stage lung cancer patients and 65 healthy individuals using 16S ribosomal RNA (rRNA) gene sequencing analysis. Bacteria can produce enzyme-active proteins that alter host cells' DNA or interact with determining cell signaling pathways regulating inflammation, cell proliferation, and apoptosis.⁶⁴ In prognostic studies, the lung microbiota's composition might be crucial. Identification and isolation of gut microbiota can be helpful for early-stage diagnosis of lung cancer.⁶⁵ *Bacillus* spp., found in lung secretions, has been associated with a higher risk of lung cancer,⁶⁶ whereas the healthy group had greater levels of *Bifidobacterium* and *Faecalibacterium*. The microbiota in the sputum and stomach are dysbiotic. When considerable amounts of fiber are consumed, the concentration of short-chain fatty acids (SCFAs) increases in the blood, sputum, and stomach, indicating their entry into the lungs and airways.⁶⁷ Overall, these findings demonstrate that microbiota is essential for developing lung cancer. Modifying the immune system and addressing the local and distal microbiota are components of a promising innovative strategy for the prevention and treatment of lung cancer.⁶⁸

The role of microbiota in specific lung cancers

Immune cells in the lungs help to maintain homeostasis, making the lung an important location of immunological-microbiota interaction. Lung cancer and bacterial dysbiosis are related, according to growing evidence from research on humans and laboratory animals.¹⁸ Lung cancer has been linked to decreased diversity, enrichment in particular genera of bacteria, and increased microbial colonies.⁶⁹ Chronic lung infection may be the primary cause of cancer when microbial dysbiosis creates more hypoxemia, a micro-

environment that augments cancer proliferation.⁷⁰ The optional anaerobic characteristics of the bacteria that preferentially colonize tumors contribute to the observation that anaerobic respiration is increased in lung cancer. These microbiotas grow and worsen disease conditions by promoting and maintaining hypoxic conditions and establishing a pro-inflammatory tumor microenvironment.⁷¹ Notably, Jin and colleagues reported an exciting finding. They attempted to establish a link between the abundance of microbiota present in airways (rather than GIT microbiota) and the number of tumors developed in the lungs.³⁷ They concluded that the local microbiota was substantially more important in the progression of lung carcinoma. Additionally, they showed that an intratracheally injected mixture of microbiota derived from developed lung malignancies significantly augmented tumor formation.³⁷

There was no change in the beta diversity between the malignant lung tissues and healthy tissues. In contrast, patients with lung cancer have exhibited a reduction in alpha diversity of the microbiota tumor microenvironment as compared to the adjacent non-malignant lung tissues (Fig. 2).

Although there is no consensus on what makes for a healthy or sick lung microbiome, several researchers have discovered intriguing links between particular microbiota species (taxonomy or genera) and lung cancer. Jin and colleagues confirmed the significance of inter-immunity exchanges of the microbiota in supporting inflammation and the growth of lung cancer in a laboratory mice model.³⁷ Tsay et al.⁷² discovered that, compared to controls, patients with lung carcinoma had higher levels of the oral bacterial population, mainly *Streptococci* and *Veillonella*. Tsay et al. found that PI3K and ERK (MAP kinase pathway) activation have been linked to the higher incidence of oral taxa. In this *in vitro* inves-

tigation, airway epithelial cells exposed to bacteria (*Veillonella*, *Prevotella*, and *Streptococci*) exhibited an upregulation of certain signaling pathways, such as ERK and PI3K pathways. Scientists attempted to link these signaling pathways to lung neoplasm as upregulation of these pathways by commensal microbiota dysbiosis promotes cancer development and progression.⁷³ The presence of *Staphylococcus* in the microbiota is rare compared to *Streptococcus*, which is previously linked with lung cancer.⁷⁴ This finding suggests that the former plays a harmful role and the latter a protective role in the growth of lung cancer. Another study, however, showed that while streptococcus may contribute to cancer prevention, *Staphylococcus* may cause DNA damage.⁷⁵ Through specific microbial components like toxins, dysregulation of lung microbial populations probably fosters alterations to carcinogenic pathways.⁷⁶ For instance, Apopa and colleagues⁷⁷ found a significant amount of cyanobacteria in non-small cell lung cancer (NSCLC) samples and linked the cyanobacteria's toxin to inflammation-associated lung cancer growth. On the other hand, Yaghoobi and colleagues⁷⁸ showed that some gram-negative bacteria's cytolethal distending toxin (CDT) have anticancer effects on A549 cell lines.

Incorporating a deeper mechanistic perspective into the review of probiotics' potential in lung cancer management can significantly enhance its scientific rigor and utility for future research. To achieve this, the manuscripts should prioritize studies that offer comprehensive molecular insights. Key among these are investigations employing molecular biology techniques such as gene expression analysis and proteomics, which can elucidate the interactions between probiotics and lung cancer cells or the tumor microenvironment. An emphasis on signaling pathways is crucial, given that probiotics often exert their effects through pathways like NF- κ B, PI3K/Akt, and MAPK, known for their roles in inflammation, cell proliferation, apoptosis, and immune responses.⁷⁹ Additionally, the impact of microbial metabolites, such as short-chain fatty acids, on cellular processes offers a layer of mechanistic detail, highlighting how these substances modulate immune responses and exhibit anti-tumorigenic properties.⁸⁰ The role of the immune system in mediating the anti-cancer effects of probiotics is another vital area of focus. Detailing the modulation of cytokine balance, activation of dendritic cells, natural killer cells, and T cells, and the potential induction of cancer cell apoptosis can provide a comprehensive overview of immune-mediated mechanisms.^{81–83}

Probiotics have shown diverse impacts on the host and its immune system. Several bacterial strains have the ability to influence the environment within the gut, the protective barrier of the intestines, and they may control the immune system of the intestinal lining. Probiotics may influence several cells that play a crucial role in both the innate and acquired immune responses, such as dendritic cells (DCs), monocytes, Natural Killer (NK) cells, macrophages, lymphocytes, and epithelial cells. Specifically, they may stimulate the pattern recognition receptors (PRRs) found on both immune cells (such as M cells in Peyer's patches) and non-immune cells (such as intestinal epithelial cells). TLRs, among PRRs, have been extensively researched due to their ability to initiate signaling cascades that result in cell proliferation and the release of cytokines, thereby regulating the immune system. Research has shown that the immune system's response to probiotic bacteria may be attributed to the production of anti-inflammatory cytokines in the gastrointestinal tract. Particular strains of probiotics have the ability to stimulate dendritic cells (DCs), which then carry the antigens to nearby lymph nodes, resulting in the production of IL-10 and IL-12. In this context, Dendritic Cells (DCs) stimulate the development of unspecialized T and B cells into their specific subgroups, using a range of cytokines. Specifically, immature Th cells have the ability to develop into Treg, Th1, and Th2 immune cells. B cells may also transform into plasma cells, which are important in humoral responses, or regulatory B (Breg) cells, that contribute

to the production of tumor growth factor (TGF)- β or IL-10. In addition, dendritic cells (DCs) may induce the activation of natural killer (NK) cells by producing cytokines including IL-12 and IL-15. Various Lactic Acid Bacteria (LAB) and other probiotic microbes may stimulate the production of IFN- γ by NK cells via the involvement of DCs.⁸⁴

Based on the contribution of probiotics to intestinal health, it is currently believed that the core benefit of probiotics is to maintain healthy intestinal flora and support a healthy immune system through nonspecific and specific physiological effects (Fig. 3).⁸⁵

Prebiotics, probiotics, and antibiotics that target bacteria

Probiotics, prebiotics, and synbiotics are examples of mature microbiome-targeting products that have just hit the commercial market and have demonstrated general safety in various clinical settings. The general effects include improved gastrointestinal steadiness, immunomodulation and obesity, and diet management by regulating microbial metabolism of dietary fibers by producing SCFAs, taking part in the digestive processes, and neutralizing inflammatory and carcinogenic agents, according to growing clinical evidence.⁸⁶ On the other hand, pharmaceutical and biotechnological sectors are looking for microbial therapeutic techniques to develop and market chemotherapeutic and targeted cancer medicines. A clinical experiment revealed a therapeutic advantage of giving neomycin concurrently with irinotecan to minimize the adverse effects of chemotherapy.⁸⁷ Chemotherapy-related side effects may be lessened by medications that target microbiomes. In different preclinical studies, small molecule inhibitors of bacterial glucuronidase were introduced to animals and were protected against diarrhea caused by anticancer drugs. However, the optimal ways to analyze the host microbiome are not well understood given the current state of research and information regarding the beneficial microbiota and molecular pathways.⁸⁸ It is yet unclear if the microbial changes may result in unanticipated localized homeostatic abnormalities, inflammatory reactions, or even precancerous lesions. The function of existing probiotic strains can be enhanced by applying bioengineering techniques which involve the artifices of a gene of a probiotic strain for promoting the clemency to the technological stress, including but not specified to high temperature, oxygen, acidification, production process, and/or survival of the probiotic in the GIT, to offer significant function to the host.⁸⁹ This advanced approach can be utilized to develop newer probiotic strains isolated from the pathogens. It permits for the development of proteins which were previously not present within the microorganism. Virulence factors of the pathogens can be reproduced and expressed into the probiotic strain and posterior administration of the attendant recombinant probiotic strain will inhibit the development of infection with no clinical expression of the signs. However, bio-engineered probiotics are able to transport therapeutics or vaccines, pathogens or toxins, promotes the immune response and imitate cell surface receptors.⁹⁰ Bioengineered probiotics are currently being researched as to target transportation of definite genes identified toward a specific foodborne pathogen. The major limitations of bioengineered probiotics are they are categorized as genetically modified organisms (GMO).⁹¹

Probiotics in the management of lung cancer

Distinct differences in the gut microbiota between lung cancer patients and healthy individuals have been documented, suggesting potential implications for prognosis and therapeutic strategies. By modifying the development of regulatory T cells, the gut microbiota may have a major impact on immunotherapy and may affect immunomodulation pathways.⁹² The same researchers discovered that using *Akkermansia muciniphila* supplements boosts immune




Fig. 3. The effects of probiotics on the host (SCFAs, short-chain fatty acids; sIgA, soluble IgA; GPR, G protein coupled free fatty acid receptor; DC cell, dendritic cell; Treg cell, regulatory T cell; Th17, T helper cell 17; ILC3, Type 3 innate lymphocyte; NK cell, Natural killer cell; LPS, lipopolysaccharide; TLR4, Toll-like receptor 4; NF-κB, nuclear factor-κB).⁸⁵

therapy responsiveness, while aberrant gut microbiota composition is linked to treatment resistance.⁹³ Immunotherapy, especially checkpoint inhibitors, has been widely applied in patients with lung cancer.⁹⁴ However, a subset of patients experiences dramatic response to these agents. The predictive factors of response to checkpoint inhibitors are the subject of debate.⁹⁵ Patients with lung cancer who react to immunotherapy have dramatically different gut flora from those who do not. Furthermore, it was demonstrated that in lung cancer patients, the predominance of the *A. muciniphila* species was positively associated with a considerably high response to anti-PD-1 therapy.^{92,93} It was further observed that a particular group of gut microbiota, namely *Firmicutes*, *Proteobacteria*, *Actinobacteria*, and *Bacteroidetes*, had boosted the response to anti-PD-1 immunotherapy.⁹⁶ This effect might be due to the stimulatory effects of probiotics on the mitochondria of immune cells,⁹⁷ which improves the immune cells' activation following immunotherapy.⁹⁸ Moreover, patients with NSCLCs who responded to nivolumab had a gut microbiota with a more varied makeup than those who did not. Additionally, it was discovered that patients with high microbiome diversity had longer progression-free survival time than patients with low microbiome diversity. A medical examination report of systemic immune disease assessed by flow cytometry showed that patients had a high concentration of CD4⁺ and CD8⁺ T cells due to higher gut microbiome diversity, especially memory and natural killer (NK) cells in response to anti-PD-1.⁹⁹ A retrospective study on 118 patients with advanced NSCLC receiving immunotherapy followed by supplementary therapy with *Clostridium butyricum* (before and after immunotherapy) demonstrated a significantly longer progression-free survival and overall survival rate.¹⁰⁰ Along with the known improvement in response to immunotherapy, these gut microbiotas can affect the lung cancer cells' response to cytotoxic chemotherapies. In a lung cancer mouse model, for instance, oral administration of *Lactobacillus acidophilus* along with the anti-cancer drug cisplatin enhanced the anti-cancer

efficacy of cisplatin by reducing the tumor size and increasing the survival rate. These findings suggest that the anti-neoplastic characteristics, such as pro-apoptotic and anti-growth activity of cisplatin, are promisingly moderated by introducing probiotics.¹⁰¹ Additionally, patients with advanced-stage lung cancer receiving *E. hirae* and *Barnesiella intestinihominis* together with chemotherapy and immunotherapy experienced prolonged progression-free survival.¹⁰² As a result, the improved immunomodulatory impact can be credited with enhanced survival of these individuals. However, further research is required to determine the involvement of the gut microbiota in the onset and lung cancer progression, as well as to study and assess the possible roles of the microbiome in the successful regulation of anticancer therapy.

Probiotic therapy and next-generation probiotics

Probiotics, defined as specific bacterial strains that enhance human health without inducing antibiotic resistance in other microbiota members, have garnered attention for their therapeutic potential. Some of the bacteria in probiotics may travel to the colon to experience the specific gut ecology, metabolisms, and physiology. Probiotics may not always require settling in the targeted organs (gut and lungs).¹⁰³ Probiotics, by definition must be safe for use in animals, tolerant to bile acids and acidity, and should be capable of adhering to and colonizing in the intestine. The information that is now available suggests that probiotic bacteria can have an impact on a range of immunological parameters, including humoral, cellular, and nonspecific immunity, as well as the immune system as a whole. New evidence suggests that probiotics affect nonspecific host defences and enhance NK cell function in aged individuals. In older mice receiving probiotic supplements, the age-associated decline in cytokine generation was shown to be reversed. Probiotics have resulted in enhanced immunomodulatory function by following several mechanisms

Table 1
Impact of probiotics, applied models (*in vitro* and *in vivo*), and major findings in the treatment of lungs tumor and metastasis.

Cells/disease	Study type	Probiotic strain/animal model	Findings	Ref.
Lewis lung carcinoma (LLC) (3 lines) and hepatoma (10lines)	<i>In vivo</i>	<i>Lactobacillus casei</i> in mice and guinea pig animal models	Increased longevity and prevention of pulmonary metastases.	104
Solid tumor (sarcoma 37) and metastatic 3LL	<i>In vivo</i>	<i>Saccharomyces cerevisiae</i> 14K and <i>Enterococcus faecium</i> K-50 (C57B16 mice and Balb/c)	Prebiotic significantly decreased metastases compared to animals that just received the vaccination.	112
Lung cancer	<i>In vivo</i>	Gene (sFlt-1 gene) transfer system through <i>Bifidobacterium infantis</i> . A recombinant technology in mice	LLC C57BL/6 mice with reduced tumor development and longer survival times.	113
Lung cancer	<i>In vivo</i>	Bacterium (<i>Bifidobacterium infantis</i>) mediated receptor (sKDR) insert in mice. sKDR is a soluble kinase insert domain receptor	By boosting the tumor's rate of necrosis and extending the mice's survival, the tumor grows less quickly (LLC C57BL/6 mice).	106
Lung metastasis of melanoma	<i>In vivo</i>	Commensal microbiota (C57BL/6 mice)	Following antibiotic therapy, changes in the microbiota led to the activation of NK cells.	114
Lung cancer	<i>In vivo</i>	<i>Lactobacillus acidophilus</i> (C57BL/6J mice)	Cisplatin's anti-tumor effects were enhanced when combined with <i>L. acidophilus</i> and diminished when combined with ABX. Probiotics and cisplatin given together boosted survival rates.	101
Breast and lungs cancer	<i>In vitro</i>	<i>Lactococcus lactis</i> NK34	>77% of cytotoxic activity.	5
Lung, breast, and cervical cancer	<i>In vitro</i>	<i>Lactococcus lactis</i> KC24	Strong cytotoxic action, excluding cells that are cervical cancer-related.	115
Melanoma	<i>In vivo</i>	<i>Bifidobacterium breve</i> , <i>B. cocktail</i> , <i>B. longum</i> , <i>B. bifidum</i> , and <i>B. lactis</i> in C57BL/6 mice	The similar level of tumor control as PD-L1-specific antibody therapy (checkpoint blockade).	116
Metastatic melanoma or non-small cell lung carcinoma (NSCLC)	<i>In vivo</i>	Germ free mice and <i>Bacteroides fragilis</i>	Immunostimulatory effects of CTLA-4 blockade.	117
Breast cancer and lung metastasis	<i>In vivo</i>	<i>Lactobacillus. casei</i> and CRL 431 BALB/c mice	Reduced tumor vascularity, extravasation of tumor cells, and lung metastasis; decreased tumor growth.	118
Breast cancer and lung metastasis	<i>In vivo</i>	Kefir used as a probiotic with fermented milk/BALB/c mice	Significantly less metastases to the lung and bone marrow and an increase in helper and cytotoxic T cells.	119
Advanced lung and ovarian cancer patients	<i>In vivo</i>	<i>Barnesiella intestinihominis</i> and <i>Enterococcus hirae</i> /C57BL/6J mice	Enhanced antitumor properties of cyclophosphamide.	102

such as influence of neutrophils and secretory IgA, induced development of mucus, activated macrophage by *Lactobacilli* signaling, inhibition of pro-inflammatory cytokine release, and by enhancing the peripheral immunoglobulin levels. Probiotics can also alter the cytokine secretion and phenotype of the DC surface. The management of toxicity, side effects, and inflammation brought on by chemotherapy in cancer patients appears to require other microorganisms. The administration of gemcitabine along with probiotics containing specific microbiota such as *Lactobacilli* and *Bifidobacteri*, has demonstrated noteworthy efficacy in the reduction of hematological toxic impact, influencing RBCs, platelet count, as well as improved aspartate aminotransferase (AST) level, gamma-glutamyl transferase (GGT), creatinine, and urea levels in mice as compared to mice receiving chemotherapy alone.¹⁰⁴ The vast majority of regularly prescribed traditional probiotics, such as *Saccharomyces* species, *Enterococcus*, *Streptococcus* *Bifidobacterium*, *Lactobacillus*, and numerous others, were selected by chance or as a result of a personal experience of an individual. Traditional probiotic administration, on the other hand, does not specifically target any disorders. Many prospective NGPs are now being developed vigorously thanks to investigations employing the most recent generation of sequencing and bioinformatics tools. A class of organisms created specifically for medicinal purposes and as novel preventive interventions is included in emerging NGPs.

Probiotics in the management of lung cancer

It is required to comprehend how the lung microbiota is associated with the wellness and disease of the lungs, including lung metastasis. Therefore, to accomplish the right diagnosis and treatment of lung carcinogenesis, discovering new therapeutic target(s)

for the lungs' microbial environment is essential.¹⁰⁵ Identifying whether the microbe has a direct role in disease pathogenesis or whether the healthy microbial population of the person declines after the onset of the disease is crucial. Though there is still a paucity of evidence supporting the prevention of lung cancer with probiotics, certain research has found promising results. According to a study, a healthy intestinal microbiota may act as a preventative measure in the treatment of cancer.¹⁰⁶ It has been suggested in a newly reviewed body of literature that metagenomics, meta-transcriptomics, and culturomics platforms are making it possible to compare the cancer patients' and healthy subjects' microbiomes. Together, the data may indicate which bacterial genera or species would be helpful to patients.¹⁰⁷ Therefore, using microorganisms or their by-products to treat cancer may also be able to treat tumors. It was found that the development of cancer-initiating toxins and metabolites by bacteria may also have a crucial role on cancer progression. In order to directly target the malignant cells in future treatments, it will be necessary to combine the use of immunotherapeutics and more traditional methods with the use of microbiomes and their products.

Radiotherapy and chemotherapy are the mainstay of cancer treatments.^{108,109} The application of chemotherapy and radiotherapy is limited by their severe adverse effects.¹¹⁰ Recently, it has been demonstrated that probiotics can be applied in reducing the adverse effects of radiotherapy and chemotherapy.¹¹¹ Table 1 summarizes the studies examining the use of probiotics in the treatment of people with the progression of lung carcinoma, animals bearing lung cancer, and a few *in vitro* research studies employing lung and other cancerous cell lines. These studies documented how probiotics affect lung metastasis, checkpoint inhibitors, homeostasis, and the increased effectiveness of

Table 2
The role of probiotics in different cancer types and the involved mechanisms.

No	Anticancer drugs	Cancer type	Antibiotic mechanism	Ref.
1.	<i>Bifidobacterium lactis</i> Bb12, <i>Lactobacillus rhamnosus</i> GG, <i>Lactobacillus rhamnosus</i> 573 <i>Bifidobacterium longum</i> , <i>Lactobacillus acidophilus</i> , <i>Enterococcus faecalis</i> <i>Lactobacillus acidophilus</i> LA-11, <i>Lactobacillus acidophilus</i>	Colorectal cancer	↓ Chronic inflammation associated with cancer ↓ WT1-expressing tumor growth ↓ Azoreductase, nitroreductase and glucuronidase activity	120,121 122 123,124
2.	<i>Propionibacterium, freudenreichii</i> subsp. <i>Shermanii</i>	Liver cancer	↓ Significantly in concentration of urinary AFB-N ⁷ -guanine	125
3.	<i>Lactobacillus reuteri</i> PTCC 1655, <i>Lactobacillus kefir</i> P-IF	Gastric cancer	Inhibits cell proliferation	126
4.	<i>Lactobacillus acidophilus</i> , <i>Bifidobacterium bifidum</i>	Cervical cancer	↑ Apoptosis ↓ Incidence of radiation-induced diarrhea	127 128
5.	<i>Clostridium butyricum</i> MIYAIRI 588	Non-small cell lung cancer	↓ Intestinal epithelial damage, Improve immune checkpoint blockade	100,129
6.	<i>Enterococcus faecium</i> 12a	Cervical cancer, lung cancer	Inhibit proliferation of cancer cells	130
7.	<i>Enterococcus thailandicus</i>	Liver cancer	Inhibition of hepatocellular carcinoma cell growth	131
8.	<i>Enterococcus mundtii</i> C4L10	Breast cancer, lung cancer and colon cancer	Apoptogenic, antimicrobial, and antiproliferative properties	132

anti-tumor drugs. Lung cancer treatment with recombinant probiotic bacteria, particularly *Bifidobacterium infantis*, have also been discussed.^{5,101,102,104,106,112–119}

Table 2 summarizes the potential therapeutic impact of diverse probiotic strains on the prevention of various cancer types. Concurrently, the table discusses the plausible anticancer effects associated with these probiotics, providing a comprehensive overview of their preventive capabilities.^{100,120–132}

Potential role of probiotics in supportive care or symptom management

The potential role of probiotics in supportive care or symptom management for lung cancer patients has gained increasing attention in recent years. Probiotics, defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host, have been explored for their ability to alleviate treatment-related side effects and improve the overall quality of life in cancer patients, including those undergoing treatment for lung cancer.

Research indicates that probiotics may play a significant role in managing gastrointestinal side effects commonly associated with cancer treatments such as chemotherapy and radiation therapy. These side effects often include diarrhea, constipation, and mucositis, which can severely impact patients' quality of life. Probiotics are thought to restore the gut microbiota balance disrupted by cancer treatments, thereby reducing the incidence and severity of these gastrointestinal symptoms. For example, a study found that probiotic supplementation reduced the severity and duration of radiation-induced diarrhea in patients with abdominal and pelvic cancers, including a subset of lung cancer patients undergoing combined chemoradiation therapy.¹²⁴ Similarly, another clinical trial demonstrated that probiotics could effectively prevent chemotherapy-induced diarrhea in cancer patients, suggesting their potential role in supportive care across various cancer types, including lung cancer.¹³³

Beyond gastrointestinal symptoms, probiotics have been investigated for their potential to enhance overall immune function, which could be compromised in lung cancer patients undergoing treatment. A robust immune system is crucial for managing infections and maintaining general health, which, in turn, can improve patients' quality of life. Research has shown that probiotic intake can increase the activity of natural killer cells and other aspects of

the immune response in elderly patients, which could be beneficial for lung cancer patients experiencing immunosuppression due to their treatment or the cancer itself.¹³⁴

Furthermore, there's a growing interest in the psychological benefits of probiotics, given the gut–brain axis's role in regulating mood and cognitive functions. Given that lung cancer patients often experience high levels of stress, anxiety, and depression, probiotics could offer a supportive care avenue to improve mental health and quality of life. A recent review had highlighted the potential of probiotics in reducing symptoms of depression and anxiety, which could be particularly relevant for patients coping with the psychological burden of cancer.¹³⁵ Overall, the exploration of probiotics as a supportive care option in lung cancer treatment is promising. Their potential to mitigate treatment-related side effects, enhance immune function, and possibly improve psychological well-being could significantly contribute to the holistic management of lung cancer patients, improving their quality of life during and after treatment. However, more targeted clinical trials and research are needed to fully understand the scope and mechanisms of probiotics in this context and to develop specific, evidence-based recommendations for their use in lung cancer patients.

Practical considerations for incorporating probiotics in lung cancer treatment protocols

Integrating probiotics into lung cancer treatment protocols presents a promising research direction with the potential for tangible clinical benefits, yet necessitating careful consideration of several practical aspects to ensure both feasibility and safety. The selection of specific probiotic strains is paramount, as their effects can vary significantly. Strains such as *Lactobacillus rhamnosus* GG and *Bifidobacterium longum* are notable for their demonstrated benefits in lung health and cancer mitigation through preclinical studies, emphasizing the importance of strain specificity.^{136,137} Additionally, the quality and viability of these strains are critical for their effectiveness, necessitating recommendations for products adhering to rigorous manufacturing standards to ensure the presence of live, active cultures.¹³⁸ However, the optimal dosing and timing for administering probiotics within lung cancer therapy remain undefined, with ongoing research aiming to establish these parameters to enhance the therapeutic benefits while minimizing potential interactions with conventional treatments.¹³⁹

The potential challenges in incorporating probiotics into cancer care include interactions with existing cancer therapies, such as chemotherapy and immunotherapy, which require a deep understanding to prevent adverse effects and safeguard patient safety.¹²⁰ Furthermore, the immunomodulatory properties of probiotics call for caution in patients with compromised immune systems, due to risks like bacteraemia or fungemia.¹⁴⁰ Another significant hurdle is the variability in probiotic formulations and the regulatory landscape across different jurisdictions, underscoring the need for standardized formulations and guidelines to facilitate clinical application.¹⁴¹ Conclusively, while the use of probiotics in lung cancer treatment schemes opens new avenues for improving patient outcomes by exploiting the gut–lung axis, the realization of their full potential hinges on the outcomes of rigorous clinical trials aimed at determining their efficacy, safety, and optimal use in this particular cohort. The successful integration of probiotics into clinical practice will likely depend on a collaborative effort among researchers, healthcare practitioners, and regulatory authorities to overcome the intricate challenges associated with their implementation in cancer care.

Key knowledge gaps and future research directions

Addressing the role of probiotics in lung cancer management, especially in terms of supportive care and symptom alleviation, necessitates a critical understanding of the limitations inherent in the current body of research, alongside a keen identification of existing knowledge gaps. These gaps not only underscore our present understanding but also chart a course for imminent research endeavors. By delineating these areas explicitly, we will be positioned to articulate specific research questions and hypotheses that could catalyze future investigative efforts, thereby enhancing our grasp and utilization of probiotics in the context of lung cancer treatment.

Among the pivotal areas awaiting exploration is the identification of optimal probiotic strains and combinations that are particularly efficacious for lung cancer patients. Despite various strains being acknowledged for their health-promoting attributes, discerning those that specifically ameliorate treatment-related side effects and bolster patient quality of life are imperative. Comparative analyses across different strains could shed light on benefits uniquely pertinent to lung cancer patient care.¹⁴² Furthermore, the establishment of effective dosing regimens and appropriate timing for probiotic administration within lung cancer therapeutic protocols remains elusive. There's a compelling need for dosing studies to devise evidence-backed guidelines that amplify probiotics' therapeutic impacts, with investigations into the timing of administration potentially optimizing efficacy and mitigating adverse reactions.¹⁴³

The interplay between probiotics and conventional lung cancer therapies, such as chemotherapy and radiation, presents a fertile ground for research into possible synergistic effects that might amplify treatment outcomes or diminish negative side effects. The dynamics between probiotics and emerging therapies, including immunotherapy, also warrant thorough exploration.¹⁴⁴ Additionally, while the advantageous effects of probiotics are increasingly acknowledged, the mechanisms underpinning these benefits, especially within the cancer treatment milieu, demand deeper investigation. Studies at the molecular and cellular levels could illuminate the interactions between probiotics, the host immune system, the microbiota, and cancer cells, providing valuable mechanistic insights.¹⁴⁵

The call for more rigorous clinical trials is unmistakable, with an emphasis on not just evaluating the safety and efficacy of probiotics for lung cancer patients but also on patient-centered outcomes such as quality of life and treatment satisfaction. These investi-

gations should account for patient diversity and the influence of variables like age, sex, cancer stage, and treatment modality on the effectiveness of probiotics.¹⁴⁶ Lastly, the long-term implications of probiotic use on lung cancer survivorship, including its potential in bolstering immune health, preventing recurrence, and enhancing overall well-being, represent a significant domain for future research.¹⁴⁷ This comprehensive approach to investigating probiotics in lung cancer management underscores a multidimensional endeavor that could significantly advance our understanding and application in this field.

Conclusions

Employing biotherapeutics for the treatment of respiratory diseases, including lung cancer, constitutes a forward-thinking approach. These microorganisms primarily alter the gut microbiota through immunomodulation. As we learn more about the relationship between micro-organisms in various organ systems and the immune system, it will be easier to design probiotic-based therapies. Even though clinical trials have produced intriguing and good results, more research is needed to identify optimal strains, precisely describe reaction apparatuses, and assess the effects of probiotics to fully realize the benefits. Specific forms and stages of lung cancer call for extensive human clinical trials. In our opinion, various probiotic bacterial strains, in combination with additional immunotherapeutic medications or different forms of therapy, may be accepted as further therapy for the prevention or management of lung cancer.

Authors' contributions

Blinded for review.

Institutional review board statement

N.A.

Informed consent statement

N.A.

Data availability statement

N.A.

Funding

N.A.

Conflicts of interest

The authors declare that they have no competing interests.

Acknowledgments

Sourav Mohanto would like to acknowledge Yenepoya (Deemed to be University), India for providing the research facilities and resources to draft the manuscript.

References

1. Zhao Y, Liu Y, Li S, Peng Z, Liu X, Chen J, et al. Role of lung and gut microbiota on lung cancer pathogenesis. *J Cancer Res Clin Oncol*. 2021;147:2177–86.
2. Elkbuli A, Byrne MM, Zhao W, Sutherland M, McKenney M, Godinez Y, et al. Gender disparities in lung cancer survival from an enriched Florida population-based cancer registry. *Ann Med Surg (Lond)*. 2020;60:680–5.

3. Viktorsson K, Lewensohn R, Zhivotovsky B. Systems biology approaches to develop innovative strategies for lung cancer therapy. *Cell Death Dis.* 2014;5:e1260.
4. Akhtar N, Bansal JG. Risk factors of lung cancer in nonsmoker. *Curr Probl Cancer.* 2017;41:328–39.
5. Han KJ, Lee NK, Park H, Paik HD. Anticancer and anti-inflammatory activity of probiotic *Lactococcus lactis* NK34. *J Microbiol Biotechnol.* 2015;25:1697–701.
6. Lee N-K, Kim S-Y, Han KJ, Eom SJ, Paik H-D. Probiotic potential of *Lactobacillus* strains with anti-allergic effects from kimchi for yogurt starters. *LWT – Food Sci Technol.* 2014;58:130–4.
7. Serban DE. Gastrointestinal cancers: influence of gut microbiota, probiotics and prebiotics. *Cancer Lett.* 2014;345:258–70.
8. Fijan S. Microorganisms with claimed probiotic properties: an overview of recent literature. *Int J Environ Res Public Health.* 2014;11:4745–67.
9. Hotel ACP, Cordoba A. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. *Prevention.* 2001;5:1–10.
10. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science.* 2012;336:1268–73.
11. Forsythe P. Probiotics and lung diseases. *Chest.* 2011;139:901–8.
12. Dickson RP, Erb-Downward JR, Martinez FJ, Huffnagle GB. The microbiome and the respiratory tract. *Annu Rev Physiol.* 2016;78:481–504.
13. Enaud R, Prevel R, Ciarlo E, Beaufils F, Wießers G, Guery B, et al. The gut–lung axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalks. *Front Cell Infect Microbiol.* 2020;10:9.
14. Gill N, Włodarska M, Finlay BB. The future of mucosal immunology: studying an integrated system-wide organ. *Nat Immunol.* 2010;11:558–60.
15. Bingula R, Filaire M, Radosevic-Robin N, Bey M, Berthon JY, Bernalier-Donadille A, et al. Desired turbulence? Gut–lung axis, immunity, and lung cancer. *J Oncol.* 2017;2017:5035371.
16. Bibbò S, Ianiro G, Giorgio V, Scaldaferrì F, Masucci L, Gasbarrini A, et al. The role of diet on gut microbiota composition. *Eur Rev Med Pharmacol Sci.* 2016;20:4742–9.
17. Nakayama J, Watanabe K, Jiang J, Matsuda K, Chao SH, Haryono P, et al. Diversity in gut bacterial community of school-age children in Asia. *Sci Rep.* 2015;5:8397.
18. Ramírez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, Pardo J, et al. The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy. *Trends Cancer.* 2020;6:86–97.
19. Anand S, Mande SS. Diet, microbiota and gut–lung connection. *Front Microbiol.* 2018;9:2147.
20. Gaudio SJ, Kumar P. Cross-talk between antigen presenting cells and T cells impacts intestinal homeostasis, bacterial infections, and tumorigenesis. *Front Immunol.* 2019;10:360.
21. Maranduba CM, De Castro SB, de Souza GT, Rossato C, da Guia FC, Valente MA, et al. Intestinal microbiota as modulators of the immune system and neuroimmune system: impact on the host health and homeostasis. *J Immunol Res.* 2015;2015:931574.
22. Dang AT, Marsland BJ. Microbes, metabolites, and the gut–lung axis. *Mucosal Immunol.* 2019;12:843–50.
23. Brown RL, Sequeira RP, Clarke TB. The microbiota protects against respiratory infection via GM-CSF signaling. *Nat Commun.* 2017;8:1512.
24. Perrone EE, Jung E, Breed E, Dominguez JA, Liang Z, Clark AT, et al. Mechanisms of methicillin-resistant *Staphylococcus aureus* pneumonia-induced intestinal epithelial apoptosis. *Shock.* 2012;38:68–75.
25. Bourlioux P, Koletzko B, Guarner F, Braesco V. The intestine and its microflora are partners for the protection of the host: report on the Danone Symposium “The Intelligent Intestine,” held in Paris, June 14, 2002. *Am J Clin Nutr.* 2003;78:675–83.
26. Johansson ME, Jakobsson HE, Holmén-Larsson J, Schütte A, Ermund A, Rodríguez-Piñero AM, et al. Normalization of host intestinal mucus layers requires long-term microbial colonization. *Cell Host Microbe.* 2015;18:582–92.
27. Weaver CT, Elson CO, Fouser LA, Kolls JK. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. *Annu Rev Pathol.* 2013;8:477–512.
28. Mantis NJ, Rol N, Corthésy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. *Mucosal Immunol.* 2011;4:603–11.
29. Frosali S, Pagliari D, Gambassi G, Landolfi R, Pandolfi F, Cianci R. How the intricate interaction among toll-like receptors, microbiota, and intestinal immunity can influence gastrointestinal pathology. *J Immunol Res.* 2015;2015:489821.
30. Huda MN, Lewis Z, Kalanetra KM, Rashid M, Ahmad SM, Raqib R, et al. Stool microbiota and vaccine responses of infants. *Pediatrics.* 2014;134:e362–72.
31. Chewing JH, Weaver CT. Development and survival of Th17 cells within the intestines: the influence of microbiome- and diet-derived signals. *J Immunol.* 2014;193:4769–77.
32. Tan HL, Rosenthal M. IL-17 in lung disease: friend or foe? *Thorax.* 2013;68:788–90.
33. Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. *Thorax.* 2011;66:144–50.
34. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. *Am J Respir Crit Care Med.* 2011;184:252–8.
35. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, Meyts I, Bullens DM, Reyniers V, et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. *Am J Transplant.* 2008;8:1911–20.
36. Gollwitzer ES, Saglani S, Trompette A, Yadava K, Sherburn R, McCoy KD, et al. Lung microbiota promotes tolerance to allergens in neonates via PD-L1. *Nat Med.* 2014;20:642–7.
37. Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, et al. Commensal microbiota promote lung cancer development via $\gamma\delta$ T cells. *Cell.* 2019;176:998–1013.e16.
38. Segal LN, Clemente JC, Tsay JC, Koralov SB, Keller BC, Wu BG, et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. *Nat Microbiol.* 2016;1:16031.
39. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. *Science.* 2013;342:967–70.
40. Steed AL, Christophi GP, Kaiko GE, Sun L, Goodwin VM, Jain U, et al. The microbial metabolite desaminotyrosine protects from influenza through type I interferon. *Science.* 2017;357:498–502.
41. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. *Proc Natl Acad Sci USA.* 2011;108:5354–9.
42. Bergs M, Völckering G, Kraska T, Pude R, Do XT, Kusch P, et al. Miscanthus $\times$ giganteus stem versus leaf-derived lignins differing in monolignol ratio and linkage. *Int J Mol Sci.* 2019;20:1200.
43. van Best N, Rolfe-Kampczyk U, Schaap FG, Basic M, Olde Damink SWM, Bleich A, et al. Bile acids drive the newborn's gut microbiota maturation. *Nat Commun.* 2020;11:3692.
44. Keren N, Konikoff FM, Paitan Y, Gabay G, Reshef L, Naftali T, et al. Interactions between the intestinal microbiota and bile acids in gallstones patients. *Environ Microbiol Rep.* 2015;7:874–80.
45. Vanhaecke L, Knize MG, Noppe H, De Brabander H, Verstraete W, Van de Wiele T. Intestinal bacteria metabolize the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine following consumption of a single cooked chicken meal in humans. *Food Chem Toxicol.* 2008;46:140–8.
46. Visconti A, Le Roy CI, Rosa F, Rossi N, Martin TC, Mohny RP, et al. Interplay between the human gut microbiome and host metabolism. *Nat Commun.* 2019;10:4505.
47. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. *Nat Rev Drug Discov.* 2011;10:671–84.
48. Weinberg F, Dickson RP, Nagrath D, Ramnath N. The lung microbiome: a central mediator of host inflammation and metabolism in lung cancer patients? *Cancers (Basel).* 2020;13:13.
49. Taghizadeh-Hesary F. “Reinforcement” by tumor microenvironment: the seventh “R” of radiobiology. *Int J Radiat Oncol Biol Phys.* 2023;S0360-3016:07940–3.
50. Cribbs SK, Uppal K, Li S, Jones DP, Huang L, Tipton L, et al. Correlation of the lung microbiota with metabolic profiles in bronchoalveolar lavage fluid in HIV infection. *Microbiome.* 2016;4:3.
51. Gao B, Gallagher T, Zhang Y, Elbadawi-Sidhu M, Lai Z, Fiehn O, et al. Tracking polymicrobial metabolism in cystic fibrosis airways: *Pseudomonas aeruginosa* metabolism and physiology are influenced by *Rothia mucilaginosa*-derived metabolites. *mSphere.* 2018;3:e00151–18.
52. Gauguier S, D'Ortona S, Ahnger-Pier K, Duan B, Surana NK, Lu R, et al. Intestinal microbiota of mice influences resistance to *Staphylococcus aureus* pneumonia. *Infect Immun.* 2015;83:4003–14.
53. Georgiou K, Marinov B, Farooqi AA, Gazouli M. Gut microbiota in lung cancer: where do we stand? *Int J Mol Sci.* 2021;22:10429.
54. Natalini JG, Singh S, Segal LN. The dynamic lung microbiome in health and disease. *Nat Rev Microbiol.* 2023;21:222–35.
55. Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. *Expert Rev Respir Med.* 2013;7:245–57.
56. Dickson RP, Huang YJ, Martinez FJ, Huffnagle GB. The lung microbiome and viral-induced exacerbations of chronic obstructive pulmonary disease: new observations, novel approaches. *Am J Respir Crit Care Med.* 2013;188:1185–6.
57. Otsu T, Nagano T, Park J, Hosomi K, Yamashita T, Tachihara M, et al. The gut microbiome as a biomarker of cancer progression among female never-smokers with lung adenocarcinoma. *Anticancer Res.* 2022;42:98–98.
58. Pizzo F, Maroccia Z, Hammarberg Ferri I, Fiorentini C. Role of the microbiota in lung cancer: insights on prevention and treatment. *Int J Mol Sci.* 2022;23:6138.
59. Goubet AG, Daillère R, Routy B, Derosa L, P MR, Zitvogel L. The impact of the intestinal microbiota in therapeutic responses against cancer. *C R Biol.* 2018;341:284–9.
60. Tang J, Xu L, Zeng Y, Gong F. Effect of gut microbiota on LPS-induced acute lung injury by regulating the TLR4/NF- κ B signaling pathway. *Int Immunopharmacol.* 2021;91:107272.
61. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell.* 2014;157:121–41.
62. Dupont C, Alpha-Bazin B, Armengaud AJ. Advanced proteomics as a powerful tool for studying toxins of human bacterial pathogens. *Toxins (Basel).* 2019;11:576.
63. Trivanović D, Pavelić K, Peršurić Ž. Fighting cancer with bacteria and their toxins. *Int J Mol Sci.* 2021;22:12980.
64. Zheng Y, Fang Z, Xue Y, Zhang J, Zhu J, Gao R, et al. Specific gut microbiome signature predicts the early-stage lung cancer. *Gut Microbes.* 2020;11:1030–42.
65. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. *Nature.* 2014;513:59–64.
66. Lu H, Gao NL, Tong F, Wang J, Li H, Zhang R, et al. Alterations of the human lung and gut microbiomes in non-small cell lung carcinomas and distant metastasis. *Microbiol Spectr.* 2021;9:e0080221.
67. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. *Nat Med.* 2014;20:159–66.

68. Carbone C, Piro G, Di Noia V, D'Argento E, Vita E, Ferrara MG, et al. Lung and gut microbiota as potential hidden driver of immunotherapy efficacy in lung cancer. *Mediat Inflamm*. 2019;2019:7652014.
69. Greathouse KL, White JR, Vargas AJ, Bliskovsky VV, Beck JA, von Muhlinen N, et al. Interaction between the microbiome and TP53 in human lung cancer. *Genome Biol*. 2018;19:123.
70. Bou Zerdan M, Kassab J, Meouchy P, Haroun E, Nehme R, Bou Zerdan M, et al. The lung microbiota and lung cancer: a growing relationship. *Cancers (Basel)*. 2022;14:4813.
71. Chen Z, Guan D, Wang Z, Li X, Dong S, Huang J, et al. Microbiota in cancer: molecular mechanisms and therapeutic interventions. *MedComm* (2020). 2023;4:e417.
72. Tsay JJ, Wu BG, Badri MH, Clemente JC, Shen N, Meyn P, et al. Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer. *Am J Respir Crit Care Med*. 2018;198:1188–98.
73. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. *Sci Transl Med*. 2010;2:26ra5.
74. Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, et al. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. *Int J Cancer*. 2018;142:769–78.
75. Urbaniak C, Gloor GB, Brackstone M, Scott L, Tangney M, Reid G. The microbiota of breast tissue and its association with breast cancer. *Appl Environ Microbiol*. 2016;82:5039–48.
76. Xu N, Wang L, Li C, Ding C, Li C, Fan W, et al. Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms. *Transl Lung Cancer Res*. 2020;9:1554–68.
77. Apopa PL, Alley L, Penney RB, Arnaoutakis K, Steliga MA, Jeffus S, et al. PARP1 is up-regulated in non-small cell lung cancer tissues in the presence of the cyanobacterial toxin microcystin. *Front Microbiol*. 2018;9:1757.
78. Yaghoobi H, Bandehpour M, Kazemi B. Apoptotic effects of the b subunit of bacterial cytolethal distending toxin on the A549 lung cancer cell line. *Asian Pac J Cancer Prev*. 2016;17(S3):299–304.
79. Smith JD, Chen A. Modulation of cancer signaling pathways by probiotics: implications for therapeutic potential. *Cancer Res*. 2020;80:2457–65.
80. Johnson T, Gupta K. The role of short-chain fatty acids in cancer prevention and therapy. *Mol Nutr Food Res*. 2019;63:e1800945.
81. Lee H, Kim J, Park JY. Probiotic modulation of the immune response in lung cancer. *Oncol Rep*. 2018;39:2332–8.
82. Williams BA, Hargreaves L, Leach ST. Using probiotics to modulate tumor progression in lung cancer: a review of experimental models. *Int J Cancer*. 2021;148:559–71.
83. Patel RM, Myers LS. Lung microbiome and cancer: implications for cancer therapy. *Cancer J*. 2019;25:215–22.
84. Cristofori F, Dargenio VN, Dargenio C, Miniello VL, Barone M, Francavilla R. Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body. *Front Immunol*. 2021;12:578386. <http://dx.doi.org/10.3389/fimmu.2021.578386>.
85. Lu K, Dong S, Wu X, Jin R, Chen H. Probiotics in cancer. *Front Oncol*. 2021;11:638148. <http://dx.doi.org/10.3389/fonc.2021.638148>.
86. Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. *Front Immunol*. 2019;10:277.
87. Hume ME. Historic perspective: prebiotics, probiotics, and other alternatives to antibiotics. *Poult Sci*. 2011;90:2663–9.
88. Lin CS, Chang CJ, Lu CC, Martel J, Ojcius DM, Ko YF, et al. Impact of the gut microbiota, prebiotics, and probiotics on human health and disease. *Biomed J*. 2014;37:259–68.
89. Tsakalidou E, Papadimitriou K. Stress responses of lactic acid bacteria. Springer Science & Business Media; 2011.
90. Berg P, Mertz JE. Personal reflections on the origins and emergence of recombinant DNA technology. *Genetics*. 2010;184:9–17.
91. Kamada N, Maeda K, Inoue N, Hisamatsu T, Okamoto S, Hong KS, et al. Non-pathogenic *Escherichia coli* strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. *Infect Immun*. 2008;76:214–20.
92. Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. *Nat Rev Clin Oncol*. 2018;15:382–96.
93. Ouyang J, Lin J, Isnard S, Fombuena B, Peng X, Marette A, et al. The bacterium *Akkermansia muciniphila*: a sentinel for gut permeability and its relevance to HIV-related inflammation. *Front Immunol*. 2020;11:645.
94. Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. *Mol Cancer*. 2023;22:40.
95. Houshyari M, Taghizadeh-Hesary F. Is mitochondrial metabolism a new predictive biomarker for antiprogrammed cell death protein-1 immunotherapy? *JCO Oncol Pract*. 2023;19:123–4.
96. Song P, Yang D, Wang H, Cui X, Si X, Zhang X, et al. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. *Thorac Cancer*. 2020;11:1621–32.
97. Mazzotta C, Tognon M, Martini F, Torreggiani E, Rotondo JC. Probiotics mechanism of action on immune cells and beneficial effects on human health. *Cells*. 2023;12:184.
98. Behnam B, Taghizadeh-Hesary F. Mitochondrial metabolism: a new dimension of personalized oncology. *Cancers (Basel)*. 2023;15:4058.
99. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinetz TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science*. 2018;359:97–103.
100. Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, et al. Association of probiotic *Clostridium butyricum* therapy with survival and response to immune checkpoint blockade in patients with lung cancer. *Cancer Immunol Res*. 2020;8:1236–42.
101. Gui QF, Lu HF, Zhang CX, Xu ZR, Yang YH. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. *Genet Mol Res*. 2015;14:5642–51.
102. Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, et al. *Enterococcus hirae* and *Barnesiella intestinihominis* facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. *Immunity*. 2016;45:931–43.
103. Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. *Nat Rev Microbiol*. 2017;15:465–78.
104. Matsuzaki T, Yokokura T, Azuma I. Anti-tumour activity of *Lactobacillus casei* on Lewis lung carcinoma and line-10 hepatoma in syngeneic mice and guinea pigs. *Cancer Immunol Immunother*. 1985;20:18–22.
105. Ong HT, Tan PK, Wang SM, Hian Low DT, Ooi LL, Hui KM. The tumor suppressor function of LECT2 in human hepatocellular carcinoma makes it a potential therapeutic target. *Cancer Gene Ther*. 2011;18:399–406.
106. Li ZJ, Zhu H, Ma BY, Zhao F, Mao SH, Liu TG, et al. Inhibitory effect of *Bifidobacterium infantis*-mediated sKDR prokaryotic expression system on angiogenesis and growth of Lewis lung cancer in mice. *BMC Cancer*. 2012;12:155.
107. Cheng M, Qian L, Shen G, Bian G, Xu T, Xu W, et al. Microbiota modulate tumoral immune surveillance in lung through a $\gamma\delta T17$ immune cell-dependent mechanism. *Cancer Res*. 2014;74:4030–41.
108. Ameri A, Norouzi S, Sourati A, Azghandi S, Novin K, Taghizadeh-Hesary F. Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer. *Cancer Rep (Hoboken)*. 2022;5:e1425.
109. Azadeh P, Gholizadeh Pasha S, Yaghobi Joybari A, Abiar Z, Alahyari S, Taghizadeh-Hesary F. Survival benefit of induction chemotherapy with paclitaxel and carboplatin followed by chemoradiation versus postoperative treatment in locally advanced gastric cancer: a retrospective cohort study. *J Gastrointest Cancer*. 2023;54.
110. Ameri A, Heydarirad G, Choopani R, Poshtmah S, Ameri P, Talebi F, et al. Sumac-rose water mouthwash versus benzydamine to prevent radiation-induced oral mucositis in head and neck cancers: a phase II randomized trial. *J Cancer Res Clin Oncol*. 2023;149:7427–39.
111. Ahren IL, Bjurberg M, Steineck G, Bergmark K, Jeppsson B. Decreasing the adverse effects in pelvic radiation therapy: a randomized controlled trial evaluating the use of probiotics. *Adv Radiat Oncol*. 2023;8:101089.
112. Tanasienko OA, Cheremshenko NI, Titova GP, Potebnya MG, Gavrilenko MM, Nagorna SS, et al. Elevation of the efficacy of antitumor vaccine prepared on the base of lectines from *B. subtilis* B-7025 upon its combined application with probiotics in vivo. *Exp Oncol*. 2005;27:336–8.
113. Zhu H, Li Z, Mao S, Ma B, Zhou S, Deng L, et al. Antitumor effect of sFlt-1 gene therapy system mediated by *Bifidobacterium infantis* on Lewis lung cancer in mice. *Cancer Gene Ther*. 2011;18:884–96.
114. Foerster F, Boegel S, Heck R, Pickert G, Rüssel N, Rosigkeit S, et al. Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells. *Oncimmunology*. 2018;7:e1409929.
115. Lee N-K, Han KJ, Son S-H, Eom SJ, Lee S-K, Paik H-D. Multifunctional effect of probiotic *Lactococcus lactis* KC24 isolated from kimchi. *LWT – Food Sci Technol*. 2015;64:1036–41.
116. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti-PD-L1 efficacy. *Science*. 2015;350:1084–9.
117. Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science*. 2015;350:1079–84.
118. Aragón F, Carino S, Perdigón G, de Moreno de LeBlanc A. Inhibition of growth and metastasis of breast cancer in mice by milk fermented with *Lactobacillus casei* CRL 431. *J Immunother*. 2015;38:185–96.
119. Zamberi NR, Abu N, Mohamed NE, Nordin N, Keong YS, Beh BK, et al. The antimetastatic and antiangiogenesis effects of kefir water on murine breast cancer cells. *Integr Cancer Ther*. 2016;15:Np53–66.
120. Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson PC, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. *Am J Clin Nutr*. 2007;85:488–96.
121. Zhong L, Zhang X, Covasa M. Emerging roles of lactic acid bacteria in protection against colorectal cancer. *World J Gastroenterol*. 2014;20:7878–86.
122. Ohigashi S, Hoshino Y, Ohde S, Onodera H. Functional outcome, quality of life, and efficacy of probiotics in postoperative patients with colorectal cancer. *Surg Today*. 2011;41:1200–6.
123. Liu Z, Qin H, Yang Z, Xia Y, Liu W, Yang J, et al. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery – a double-blind study. *Aliment Pharmacol Ther*. 2011;33:50–63.
124. Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. *Br J Cancer*. 2007;97:1028–34.

125. El-Nezami HS, Polychronaki NN, Ma J, Zhu H, Ling W, Salminen EK, et al. Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China. *Am J Clin Nutr.* 2006;83:1199–203.
126. Rasouli BS, Ghadimi-Darsajini A, Nekouian R, Iragian GR. In vitro activity of probiotic *Lactobacillus reuteri* against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression. *J Cancer Res Ther.* 2017;13:246–51.
127. Ghoneum M, Felo N. Selective induction of apoptosis in human gastric cancer cells by *Lactobacillus kefir* (PFT), a novel kefir product. *Oncol Rep.* 2015;34:1659–66.
128. Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E, Lorvidhaya V. Randomized controlled trial of live *Lactobacillus acidophilus* plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. *Radiat Oncol.* 2010;5:31.
129. Chen H, Ma X, Liu Y, Ma L, Chen Z, Lin X, et al. Gut microbiota interventions with *Clostridium butyricum* and norfloxacin modulate immune response in experimental autoimmune encephalomyelitis mice. *Front Immunol.* 2019;10:1662.
130. Sharma P, Kaur S, Chadha BS, Kaur R, Kaur M, Kaur S. Anticancer and antimicrobial potential of enterocin 12a from *Enterococcus faecium*. *BMC Microbiol.* 2021;21:39.
131. Al-Madbolay LA, El-Deeb NM, Kabbash A, Nael MA, Kenawy AM, Ragab AE. Purification, characterization, identification, and anticancer activity of a circular bacteriocin from *Enterococcus thailandicus*. *Front Bioeng Biotechnol.* 2020;8:450.
132. Yusuf MA, Ichwan SJA, Hamid THA. Anti-proliferative activities of purified bacteriocin from enterococcus mundtii strain C4I10 isolated from the caecum of Malaysian non-broiler chicken on cancer cell lines. *Int J Pharm Pharm Sci.* 2015;7:334–7.
133. Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of radiation-induced diarrhea. *World J Gastroenterol.* 2007;13:912–5.
134. Wada M, Nagata S, Saito M, et al. Effects of the enteral administration of *Bifidobacterium breve* on patients undergoing chemotherapy for pediatric malignancies. *Support Care Cancer.* 2010;18:751–9.
135. Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. *Ann Gen Psychiatry.* 2017;16:14.
136. Westfall S, Lomis N, Kahouli I, Dia SY, Singh SP, Prakash S. **Lactobacillus rhamnosus* GG* supplementation modulates the immune response to respiratory infections in healthy individuals: a randomized, double-blind, placebo-controlled trial. *Eur J Clin Nutr.* 2019;73:833–9.
137. Urbanska AM, Bhathena J, Martoni C, Prakash S. Estimation of the potential antitumor activity of microencapsulated **Lactobacillus acidophilus** yogurt formulation in the prevention of cancer. *Res Microbiol.* 2010;161:480–4.
138. Gøbel RJ, Larsen N, Jakobsen M, Mølgaard C, Michaelsen KF. Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome. *J Pediatr Gastroenterol Nutr.* 2012;55:673–8.
139. Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M, Kitay-Cohen Y. Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. *Nutrition.* 2011;27:177–81.
140. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomized, double-blind, placebo-controlled trial. *Lancet.* 2008;371:651–9.
141. Sanders ME, Guerner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, et al. An update on the use and investigation of probiotics in health and disease. *Gut.* 2013;62:787–96.
142. Jones RM, Mercante JW, Neish AS. Reactive oxygen production induced by the gut microbiota: pharmacotherapeutic implications. *Curr Med Chem.* 2012;19:1519–29.
143. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA.* 2012;307:1959–69.
144. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science.* 2018;359:91–7.
145. Plaza-Díaz J, Álvarez-Mercado AI, Ruiz-Marín CM, et al. Molecular mechanisms of action of probiotics in the prevention and treatment of colorectal cancer. *Nutrients.* 2019;11:2453.
146. Urbancsek H, Kazar T, Mezes I, Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiofilus in patients with radiation-induced diarrhoea. *Eur J Gastroenterol Hepatol.* 2001;13:391–6.
147. Gupta A, Khanna S. Fecal microbiota transplantation. *JAMA.* 2017;318:102.